Prenatal Care: Screening for Human Immunodeficiency Virus (HIV) (NQF 0012)

EMeasure Name Prenatal Care: Screening for Human Immunodeficiency Virus (HIV) EMeasure Id CAF0A28E-8875-401A-B59B-95DAE1E3FA47
Version number 1 Set Id D4D6A7A4-88F8-4D6E-AB3E-09F80C3D4EB5
Available Date No information Measurement Period January 1, 20xx through December 31, 20xx
Measure Steward American Medical Association - Physician Consortium for Performance Improvement
Endorsed by National Quality Forum
Description Percentage of patients, regardless of age, who gave birth during a 12-month period who were screened for HIV infection during the first or second prenatal visit
Copyright
© 2010 American Medical Association.  All Rights Reserved
Measure scoring Proportion
Measure type Process
Stratification
None
Risk Adjustment
None
Data Aggregation
Rationale
While the number of perinatally transmitted cases of HIV has decreased, perinatal transmission still accounts for the majority of new cases of HIV in children. 
Benefits of knowing a woman’s HIV status early on in pregnancy have been well documented and allow the health care provider to initiate treatment early on in the pregnancy, thereby decreasing the risk of transmission of HIV to the child.
Clinical Recommendation Statement
Universal HIV testing with patient notification should be a routine component of prenatal care; however, this must be in accordance with current state laws (ACOG/AAP). PHS recommends that all pregnant women in the United States be tested for HIV infection. All health-care providers should recommend HIV testing to all of their pregnant patients, pointing out the substantial benefit of knowledge of HIV status for the health of women and their infants. HIV screening should be a routine part of prenatal care for all women (CDC). Clinicians should screen all pregnant women for HIV. There is good evidence that both standard and FDA-approved rapid screening tests accurately detect HIV infection in pregnant women and fair evidence that introduction of universal prenatal counseling and voluntary testing increases the proportion of HIV-infected women who are diagnosed and are treated before delivery (USPSTF) (A Recommendation).
Improvement notation
Higher score indicates better quality
Measurement duration
12 month(s)
Reference
American Academy of Pediatrics and American College of Obstetricians and Gynecologists. Guidelines for Prenatal Care, 5th Edition. Elk Grove Village, IL, AAP/ACOG, 2002.
Reference
A Brief Evidence Update for the U.S. Preventive Services Task Force. Available at: www.preventiveservices.ahrq.gov. Accessed November 2005.
Reference
US Preventive Services Task Force. Guide to Clinical Preventive Services. 3rd ed. Baltimore, Md: Williams amp; Wilkins; 2000-2002.
Reference
CDC. Revised recommendations for HIV screening of pregnant women. MMWR 2001; 50(No. RR-19). Available at: http://www.cdc.gov.mmwr/. Accessed November 2005.
Definition
Guidance
The purpose of the data element "Estimated date of conception" <= 10 months starts before or during "Procedure Performed: Delivery of Live Birth" is to establish the date when the pregnancy began.  We have included the timeframe of 10 months prior to the delivery date to link the estimated date of conception to the delivery that occurred during the measurement period (to ensure it isn’t the estimated date of conception for a previous pregnancy).

Table of Contents


Population criteria

Data criteria (QDS Data Elements)

Summary Calculation

Calculation is generic to all measures:



Measure set CLINICAL QUALITY MEASURE SET 2011-2012